Heikki Joensuu

University of Helsinki — Finland

Medicine · Health Sciences

126h-index73.3kcitations1.1kworks2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastrointestinal Tumor Research and Treatment(200), Breast Cancer Treatment Studies(136), HER2/EGFR in Cancer Research(124), Gastric Cancer Management and Outcomes(83), Cancer Genomics and Diagnostics(80)

Publications1.1k total

Corrigendum to Mutant p53–associated myosin-X upregulation promotes breast cancer invasion and metastasis
Journal of Clinical Investigation·2025Open Access
Supplementary Figures from HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer
2025Open Access
Supplementary Data Legends from HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer
2025Open Access
Supplementary Figure S3 from <i>KIT</i> and <i>PDGFRA</i> Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025Open Access
Study Protocol from <i>KIT</i> and <i>PDGFRA</i> Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025Open Access
Supplementary Figure S2 from <i>KIT</i> and <i>PDGFRA</i> Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025Open Access
Supplementary Figure S1 from <i>KIT</i> and <i>PDGFRA</i> Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025Open Access
Supplementary Table S1 from <i>KIT</i> and <i>PDGFRA</i> Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025Open Access
DOSE CALCULATION AND EFFECT PROBABILITY MODELS TO THE OPTIMISATION OF GLIOBLASTOMA TREATMENTS WITH BNCT
International Journal of Particle Therapy·2025Open Access
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)
Future Oncology·2025Open Access
Publisher Correction: Academia Europaea’s guidelines for the visualization of clinical outcomes
Nature Medicine·2025Open Access
Academia Europaea’s guidelines for the visualization of clinical outcomes
Nature Medicine·2025
Predictive factors of oral mucositis in patients with locally recurrent inoperable head and neck cancer treated with boron neutron capture therapy
Acta Oncologica·2025· 1 citedOpen Access
Response to the letter to the editor titled: “Polyploid giant cancer cells: unveiling a latent axis of resistance and tumor evolution in HER2-targeted therapy”
Cancer Letters·2025
Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates
Cancer Letters·2025· 10 citedOpen Access
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
Nature Cancer·2025· 4 cited
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data
BMJ Oncology·2025· 2 citedOpen Access
Interferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data.
Journal of Clinical Oncology·2025
Darolutamide plus androgen deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
Journal of Clinical Oncology·2025· 1 cited
MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial.
Journal of Clinical Oncology·2025
page 1 of 55Next →

Frequent Co-authors

George D. Demetri(10), Peter Hohenberger(10), Peter Reichardt(10), Paolo G. Casali(9), Jean‐Yves Blay(9), Margaret von Mehren(8), Sebastian Bauer(8), Angelo Paolo Dei Tos(8), Alessandro Gronchi(8), Piotr Rutkowski(8), Christopher L. Corless(7), Sylvie Bonvalot(7), Mikael Eriksson(7), Hans Gelderblom(7), Patrick Schöffski(7), Kirsten Sundby Hall(7), Charles D. Blanke(6), Peter Roberts‎(6), Christopher D.�M. Fletcher(6), N. Abecassis(6)